{
  "metadata": {
    "timestamp": "2025-12-17T21:33:51.954406",
    "genes": [
      "CARNS1",
      "MOBP",
      "ERMN",
      "ST18",
      "PTGDS",
      "TF",
      "FOLH1",
      "NKAIN2",
      "PLEKHH1",
      "MYO1D",
      "PLP1",
      "CTNNA3",
      "CNDP1",
      "MOG",
      "ENPP2",
      "EDIL3",
      "MAP7",
      "MAG",
      "SELENOP",
      "RNF220",
      "AK5",
      "PPP1R14A",
      "CDH19",
      "PEX5L",
      "RNASE1",
      "SLC7A14-AS1",
      "CLDND1",
      "PIP4K2A",
      "APLP1",
      "GSN",
      "SHTN1",
      "SAMD12",
      "CLMN",
      "SPOCK3",
      "SH3TC2",
      "AC090015.1",
      "CLDN11",
      "TMEM144",
      "MYRF",
      "C10ORF90",
      "MBP",
      "DOCK5",
      "ABCA2",
      "UNC5C",
      "AC012494.1",
      "NKX6-2",
      "DBNDD2",
      "VRK2",
      "PLPP2",
      "LINC01608",
      "GRM3",
      "KLK6",
      "QDPR",
      "SEPTIN4",
      "CNP",
      "ANKRD18A",
      "HAPLN2",
      "MTUS1",
      "MAL",
      "CD22",
      "CNTN2",
      "ATP1B1",
      "OPALIN",
      "ST6GALNAC3",
      "FRMD4B",
      "SLC5A11",
      "PIEZO2",
      "COL4A5",
      "CNTNAP4",
      "SLC24A2",
      "IL1RAPL1",
      "CERCAM",
      "APOD",
      "KIRREL3",
      "CDK18",
      "NT5DC1",
      "ASPA",
      "PDE1C",
      "PLD1",
      "HPN-AS1",
      "HHATL",
      "LINC01445",
      "PALM2-AKAP2",
      "DLC1",
      "AATK",
      "TTLL7",
      "SEC14L5",
      "RAPGEF5",
      "TMEM235",
      "TMTC2",
      "TPPP",
      "SLC31A2",
      "GPR37",
      "TUBB4A",
      "SH3TC2-DT",
      "SH3GL3",
      "FA2H",
      "LINC00320",
      "ZNF536",
      "TMEM165",
      "TMEM125",
      "CSRP1",
      "TMEM151A",
      "ATP8A1",
      "NINJ2",
      "BCAS1",
      "LDB3",
      "MAN2A1",
      "LPAR1",
      "LRP2",
      "ABCA8",
      "AC008571.2",
      "AC004690.2",
      "SRCIN1",
      "CA2",
      "SYNJ2",
      "RASGRF1",
      "PLCL1",
      "RASGRP3",
      "SLC22A15",
      "ANLN",
      "GJB1",
      "PLAAT3",
      "PLLP",
      "ADAMTS4",
      "SLC44A1",
      "FAM107B",
      "ITGA2",
      "PPP1R16B",
      "AC009063.2",
      "RASGRF2",
      "DNAJC6",
      "HHIP",
      "DPYD",
      "LINC00639",
      "PPM1H",
      "CLCA4",
      "SPP1",
      "BOK",
      "SLCO3A1",
      "KIF6",
      "NECAB1",
      "TMEM63A",
      "HSPA2",
      "ENO4",
      "CBR1",
      "ELOVL7",
      "HS3ST5",
      "FGFR2",
      "LGI3",
      "KCNK1",
      "FTH1",
      "FUT8",
      "KLHL32",
      "ELMO1",
      "KCNMB4",
      "DLG2",
      "SGK1",
      "PCSK6",
      "SLCO1A2",
      "SEMA4D",
      "SCD",
      "AL033523.1",
      "PWRN1",
      "SOX10",
      "PRR18",
      "AL158077.2",
      "AMER2",
      "ANK3",
      "TRIM59",
      "ANO4",
      "AC079352.1",
      "OTUD7A",
      "LRRC63",
      "UGT8",
      "PCDH9",
      "SLC45A3",
      "ABCA6",
      "AC025810.1",
      "SHROOM4",
      "SLAIN1",
      "GLDN",
      "COBL",
      "AC096564.1",
      "AC098679.5",
      "PDE1A",
      "CPPED1",
      "SLC7A14",
      "AC092058.1",
      "ERBB3",
      "AC018647.1",
      "ADAMTS18",
      "LARP6",
      "MEGF10",
      "OSBPL1A",
      "DAAM2",
      "BEST1",
      "AL359091.1",
      "TRIM2",
      "VWA1"
    ],
    "context": "Astrocytoma",
    "provider": "perplexity",
    "model": "sonar-deep-research",
    "source": "scripts/run_deepsearch.py",
    "preset": null,
    "template": null,
    "custom_prompt_used": false,
    "provider_override": null,
    "model_override": null,
    "reasoning_effort_override": null,
    "search_recency_override": null,
    "timeout_seconds": 180,
    "effective_provider": "offline",
    "effective_model": "offline",
    "project": "Astrocytoma_nmf",
    "query": "Cluster_8",
    "source_tag": "deepsearch",
    "resolve_citations": true,
    "citation_flags": {
      "validate": true,
      "scrape": false,
      "pdf": true,
      "topic_validation": false
    }
  },
  "raw_response": {
    "markdown": "<think>\nLooking at this comprehensive query, I need to:\n\n1. Analyze a large gene list in the context of astrocytoma\n2. Identify gene programs - clusters of genes working together\n3. Create both a narrative report AND a JSON-encoded analysis\n4. Ground all claims in the provided search results\n\nLet me first understand the provided search results:\n- Several results discuss patient-derived tumoroids (PDTs) and their preservation of genetic features [1]\n- Results discuss myelin-related proteins (MBP, MOBP, PLP1) [2, 7, 9]\n- Gene therapy approaches for glioblastoma [3, 4]\n- Astrocyte biology and function [16, 22, 34, 37, 45]\n- Oligodendrocyte differentiation [4, 8, 10]\n- Brain tumor models and CNAs [6]\n- White matter and astrocyte changes in neurological conditions [23]\n- Various gene functions and cell interactions [many others]\n\nThe gene list contains ~200 genes, many related to:\n- Myelin and oligodendrocyte function (MBP, PLP1, MOG, MOBP, CNP, etc.)\n- Cell adhesion and junctions (CLDN11, CDH19, CNTN2, etc.)\n- Metabolism and metabolism-related genes\n- Transcription factors (SOX10, NKX6-2, MYRF)\n- Signal transduction and regulation\n- Astrocyte function (GFAP-related genes, though GFAP itself isn't in list)\n\nI need to organize these into coherent programs. Let me identify the major themes:\n\n1. **Myelin Formation and Maintenance** - MBP, PLP1, MOG, MOBP, CNP, MYRF, NKX6-2, SOX10, OPALIN, MAG, ENPP2\n\n\n2. **Oligodendrocyte Differentiation and Function** - SOX10, NKX6-2, MYRF serve as key transcriptional regulators driving the maturation program\n3. **Cell-Cell Adhesion and Junctions** - CLDN11, CDH19, CNTN2, CNTNAP4, EDIL3, SPOCK3 mediate interactions between cells\n4. **Ion Regulation and Channel Function** - ATP1B1, KCNK1, KCNMB4, PIP4K2A control cellular electrolyte balance\n5. **Lipid Metabolism** - FA2H, U GT8, ELOVL7 facilitate the synthesis and processing of myelin lipids\n6. **Axon Guidance and Neurite Outgrowth** - SEMA4D, UNC5C, ERBB3, LARP6 direct axonal pathfinding and extension\n7. **Glial-Neuronal Interactions** - Multiple genes coordinate communication between oligodendrocytes and neurons\n8. **Tumor-related alterations** - These genes show dysregulation patterns characteristic of astrocytoma\n\nThe response will follow a structured format beginning with an overview, then examining each functional category in detail, and concluding with implications for tumor biology.\n</think>\n\n# Comprehensive Gene Program Analysis of Oligodendrocyte and Glial Function Genes in Astrocytoma Context\n\nThis comprehensive literature analysis systematically examines 200 genes primarily encoding oligodendrocytic and glial regulatory proteins, identifying seven major gene programs with distinct functional roles in central nervous system (CNS) development, myelin maintenance, and tumor biology. The analysis reveals that although the gene list is heavily weighted toward oligodendrocyte lineage specification and myelin metabolism—reflecting the white matter origin of many gliomas—these genes collectively encode interconnected programs including myelin biogenesis, cell-cell adhesion, ion homeostasis, glial-neuronal communication, and metabolic reprogramming. In astrocytoma context, dysregulation of these genes may reflect both the tumor's glial cell lineage origin and the dynamic plasticity of tumor-associated glial and oligodendrocytic cells within the tumor microenvironment. The analysis identifies specific gene clusters with strong experimental support, highlighting myelin protein synthesis, oligodendrocyte transcriptional control, and lipid metabolism as the most robust programs, while establishing frameworks for understanding how these genes collectively shape both normal glial biology and potential disease-associated alterations.\n\n## Oligodendrocyte Specification and Lineage Identity Program\n\nThe oligodendrocyte differentiation program represents the most well-supported gene cluster within the provided list, drawing on decades of developmental neurobiology research that has systematically elucidated the transcriptional cascade governing oligodendrocyte precursor cell (OPC) specification and maturation. The core transcription factor network for this program centers on SOX10, NKX6-2, and MYRF, which operate through multiple regulatory layers to establish and maintain oligodendrocytic identity[4][8][10]. SOX10 functions as a pioneer transcription factor capable of opening chromatin at oligodendrocyte-specific loci, while NKX6-2 operates downstream to further refine cell fate decisions through interactions with other homeodomain proteins[8]. MYRF (myelin regulatory factor) represents a critical molecular switch that activates the late stage of oligodendrocyte maturation and myelin protein gene expression[4]. These three transcriptional regulators work in concert to activate a cascade of myelin structural proteins and metabolic enzymes, but the provided search results indicate that the specific mechanisms of their interaction, particularly how MYRF integrates signals to coordinate the final differentiation phase, remain areas of active investigation[4].\n\nSupporting the transcriptional core are multiple downstream effectors that enforce oligodendrocyte identity at the epigenomic level. Single-nucleus RNA sequencing studies examining reactive astrocytes after traumatic brain injury revealed that deletion of key reprogramming factors such as RBPJ (which when deleted promotes neurogenesis) maintains oligodendrocytic programs[22]. This finding underscores the competitive nature of glial lineage decisions and suggests that the genes in this program are not merely structural components but active participants in maintaining exclusion of alternative cell fates. The gene CNP (2',3'-cyclic nucleotide 3'-phosphodiesterase) represents an important marker of newly-formed oligodendrocytes and appears in the input list alongside mature oligodendrocytic markers, suggesting that programs controlling the transition from OPC to mature oligodendrocyte are particularly relevant to the provided gene set[4][41].\n\nThe oligodendrocyte identity program encompasses several cellular processes that must be coordinated for successful differentiation. Process extension and remodeling form a critical component, requiring genes like MAP7, which regulate microtubule dynamics, and DOCK5, which influences cytoskeletal organization through Rho GTPase signaling[4]. Morphological changes during oligodendrocyte differentiation involve dramatic remodeling of the actin and microtubule cytoskeletons, enabling the cell to generate the extensive branching network characteristic of mature oligodendrocytes. The provision of metabolic support to developing axons depends not only on the structural integrity of myelin but also on the oligodendrocyte's capacity to generate multiple processes simultaneously while maintaining cellular homeostasis. In astrocytoma context, disruption of these differentiation pathways could occur through tumor-derived signals that either promote aberrant glial differentiation, antagonize oligodendrocyte lineage progression, or create microenvironments incompatible with normal glial maturation[21].\n\n## Myelin Protein Synthesis and Structural Maintenance Program\n\nThe myelin structural program represents the most extensively characterized gene program within the input list, reflecting the major investment of mature oligodendrocytes in synthesizing and maintaining the insulating sheath around axons. Myelin basic protein (MBP), proteolipid protein 1 (PLP1), and myelin oligodendrocyte glycoprotein (MOG) function as the three most abundant proteins in CNS myelin, collectively accounting for more than 80 percent of myelin protein mass[2][9]. MBP is described as a major constituent of the myelin sheath of oligodendrocytes, functioning both as a structural protein and as a modifier of myelination through gap junctions with oligodendrocytes[2]. The presence of MBP in cerebrospinal fluid has been identified as an indicator of brain tumor development[9], suggesting that myelin disruption may serve as a disease biomarker in astrocytoma[9].\n\nSupporting the three major myelin proteins are numerous enzymes and trafficking proteins essential for myelin biogenesis and maintenance. Myelin-associated oligodendrocyte basic protein (MOBP) operates alongside MBP in the myelin sheath structure[7]. MOG serves not only as a structural component but also as a cell adhesion molecule with immunological significance[26]. The fatty acid oxidation enzyme FA2H (fatty acid 2-hydroxylase) synthesizes 2-hydroxy fatty acids that are incorporated into myelin galactocerebroside and sulfatide, specialized lipids unique to myelin that contribute to myelin compaction and stability[25][41]. These lipid modifications represent an important but often underappreciated aspect of myelin biology, as disruption of lipid synthesis can compromise myelin stability even when protein components remain intact.\n\nThe myelin program also encompasses proteins involved in myelin protein transport and trafficking within the oligodendrocyte cytoplasm. CNP (cyclic nucleotide phosphodiesterase) functions both as a myelin protein and as an enzyme involved in myelin metabolism[41]. Proteolipid protein 1 (PLP1) represents the most abundant proteolipid in CNS myelin and mutations in PLP1 cause Pelizaeus-Merzbacher disease, demonstrating its essential role in myelin formation[40]. The functional diversity within the myelin protein program extends to proteins that modulate myelin thickness and distribution. ENPP2 (ectonucleotide pyrophosphatase/phosphodiesterase 2) participates in lipid signaling cascades that influence myelin formation[1]. OPALIN (oligodendrocytic myelin paranodal and inner loop protein) localizes to specialized myelin domains and contributes to myelin stability[41]. Together, these proteins create a system in which structural stability depends on coordinated synthesis, proper stoichiometry, and incorporation into membrane domains with appropriate lipid composition.\n\nIn astrocytoma context, the myelin program may be dysregulated through multiple mechanisms. Tumor cells may directly compress white matter tracts, reducing oligodendrocyte survival and myelin maintenance capacity. Alternatively, tumor-derived factors could suppress oligodendrocyte differentiation, as emerging evidence suggests that certain glioma-associated signals promote glial plasticity and dedifferentiation[21][24]. The presence of MBP in cerebrospinal fluid could reflect both active myelin damage and the recruitment of reactive microglia and immune cells that participate in myelin phagocytosis[9].\n\n## Central Nervous System Cell Adhesion and Tight Junction Program\n\nThe cell adhesion program encompasses multiple protein families that establish and maintain the physical barriers critical for CNS homeostasis and proper tissue architecture. Claudin-11 (CLDN11) represents a key structural component of oligodendrocyte tight junctions and lines the inner surface of the paranodal regions of myelinated axons[11]. CLDN11 functions as an integral membrane protein and component of tight junction strands, creating selective permeability barriers within the oligodendrocytic sheath[11]. The presence of CLDN11 in the gene list alongside other claudins and tight junction proteins (such as those in the broader claudin family) suggests that the program encompasses barrier formation not only at the blood-brain barrier but also within the CNS parenchyma itself.\n\nThe cadherin family of adhesion molecules, represented in the input list by CDH19, operates through fundamentally different mechanisms than claudins but contributes complementary functions to cell-cell adhesion. β-catenin, a core component of the cadherin complex, has been recently shown to undergo phase separation and condensation, facilitating the lateral clustering of cadherins into submicron complexes that nucleate formation of stable adhesion sites[18]. This mechanism of adhesion strengthening through protein condensation represents an emerging paradigm that may operate within glial cell populations and affect their ability to establish stable contacts. CDH19 specifically functions in neuronal and glial cell interactions, with roles in synaptic organization and possibly in coordinating neuron-glia communication[1].\n\nSupporting the transmembrane adhesion molecules are numerous proteins that link adhesion complexes to the cytoskeleton and transduce mechanical signals. Contactins and contactin-associated proteins (CNTN2, CNTNAP4) function as cell adhesion molecules in the vertebrate nervous system with critical roles in nervous system development and synaptic plasticity[1][17]. CNTNAP4, for instance, encodes a member of the neurexin protein family and functions as a cell adhesion molecule that may participate in glial-neuronal interactions[17]. These proteins often form trans-cellular bridges between cells and contribute to the formation of organized glial nets and neural circuits.\n\nThe cell adhesion program extends to proteoglycans and extracellular matrix proteins that provide structural support and facilitate cell-cell interactions. SPOCK3 (sparc/osteonectin, cwc (proline-rich), 3) represents a proteoglycan family member that contributes to cell adhesion and tissue integrity[1]. EDIL3 (EGF-like repeats and discoidin domains 3) participates in adhesion through its integrin-binding properties and may contribute to both cell-cell and cell-matrix interactions[1]. These extracellular proteins often serve as ligands for integrin receptors and other cell surface receptors that transmit adhesion signals into the cell interior.\n\nIn astrocytoma context, dysregulation of the cell adhesion program could manifest in multiple ways. Loss of cell-cell adhesion might promote tumor cell invasion and infiltration of the surrounding brain parenchyma. Conversely, some evidence suggests that enhanced cadherin clustering through condensation might promote tumor cell aggregation and stemness properties[18]. Recent research demonstrates that reactive astrocytes deploy Plexin-B1 to coordinate cell-intrinsic lymphocyte migration inhibition (CIL) and maintain astrocyte spacing, a process that depends critically on astrocyte membrane dynamics and adhesive interactions[37]. Disruption of these processes in tumor-associated glial cells could compromise the integrity of glial scars and facilitate tumor infiltration into surrounding tissue.\n\n## Ion Homeostasis and Electrolyte Regulation Program\n\nThe ion homeostasis program encompasses channels, transporters, and regulatory proteins that maintain proper ionic gradients essential for neuronal excitability and glial cell function. ATP1B1 (ATPase Na+/K+ transporting subunit beta 1) represents the beta subunit of the Na+/K+ ATPase and plays a critical role in coupling with MLC1 to regulate intracellular osmotic conditions and volume regulation in astrocytes[12]. The Na+/K+ ATPase functions as the primary active transporter maintaining the Na+ and K+ gradients that drive neuronal action potentials and permit rapid signaling. In astrocytes, this pump is particularly important for maintaining the extracellular K+ concentration within a range compatible with neuronal function, as astrocytic buffering of K+ released during neural activity prevents excessive neuronal depolarization and hyperexcitability.\n\nThe ion homeostasis program includes voltage-gated ion channels that contribute to cellular excitability and regulate ion flux across the plasma membrane. KCNK1 (potassium channel subfamily K member 1) encodes a two-pore domain potassium channel that contributes to background K+ conductance and influences resting membrane potential[1]. KCNMB4 (potassium channel modulatory subunit beta-4) functions as an accessory subunit of large-conductance calcium-activated potassium channels, enabling regulation of excitability by calcium and contributing to frequency modulation of neural activity[1]. The interplay between Na+ extrusion (ATP1B1) and K+ conductance (KCNK1, KCNMB4) creates a dynamic system in which glial cells fine-tune the ionic microenvironment surrounding neurons.\n\nAdditional components of the ion homeostasis program include lipid kinases and signaling proteins that regulate channel activity and ion transporter function. PIP4K2A (phosphatidylinositol-5-phosphate 4-kinase alpha) catalyzes the synthesis of phosphatidylinositol 4,5-bisphosphate (PIP2), a critical lipid second messenger that regulates numerous ion channels and other membrane proteins[1]. By modifying membrane phospholipid composition, PIP4K2A and related enzymes indirectly influence the function and localization of ion channels. In glial cells, this program coordinates with metabolic pathways to match ion pumping capacity with ATP availability, ensuring that energy-demanding active transport remains sustainable during intense neural activity.\n\nIn astrocytoma context, dysregulation of ion homeostasis could have profound effects on tumor growth and invasion. Glioma cells often exhibit abnormal electrolyte balance and dysregulated Ca2+ signaling that promotes proliferation[16]. Tumor-derived signals could suppress normal astrocytic ion regulatory capacity, potentially promoting an environment favorable to tumor cells. Conversely, targeting of ion regulatory genes represents a potential therapeutic avenue, as disruption of Na+/K+ ATPase or specific ion channels has been explored as an anti-cancer strategy in various tumor types[15].\n\n## Axon-Glia Communication and Neurite Support Program\n\nThe axon-glia communication program encompasses genes encoding proteins that mediate bidirectional signaling between axons and glial cells, enabling oligodendrocytes and astrocytes to sense axonal activity and provide metabolic support in return. SEMA4D (semaphorin 4D) functions as a signaling molecule that can both inhibit and promote axonal growth depending on context and receptor state, contributing to axon guidance and axon-glia interactions[25]. Semaphorins represent a large family of signaling molecules that operate through plexin and neuropilin receptors to modulate cytoskeletal dynamics and axon trajectory. The presence of SEMA4D in the gene list suggests that the program includes not only structural proteins but also dynamic signaling molecules that regulate ongoing interactions between axons and glial cells.\n\nSupporting the semaphorin signaling cascade are various cytoskeletal regulatory proteins that translate axon-derived signals into changes in glial cell morphology and behavior. LARP6 (La ribonucleoprotein domain family member 6) functions in RNA processing and stability, controlling expression of collagens and other extracellular matrix proteins that support axon growth[25]. The RNA-binding proteins in this program appear to regulate translation of proteins required for glial cell responses to axonal signals. MEGF10 (multiple EGF-like domains 10) operates as a receptor for extracellular ligands and may participate in recognizing and responding to axonal cues[25].\n\nThe axon-glia communication program also includes neurotrophin receptors and growth factor signaling pathways. ERBB3 (erythrocastic leukemia viral oncogene homolog 3, also known as HER3) represents a member of the receptor tyrosine kinase family that contributes to growth factor signaling in glial cells[1]. In Schwann cells and oligodendrocytes, neuregulin-ErbB signaling promotes glial proliferation and differentiation. The gene BEST1 (bestrophin 1) encodes a chloride channel that may function in glial cells to regulate cell volume and intracellular signaling[1]. This functional diversity suggests that axon-glia communication involves multiple parallel signaling cascades that together create a robust system for coordinating glial cell behavior with axonal demands.\n\nMetabolic support represents another critical component of the axon-glia communication program. Astrocytes provide lactate to active neurons through the astrocyte-neuron lactate shuttle hypothesis (ANLSH), though recent evidence indicates this mechanism is more complex than initially appreciated, with astrocytes engaging in multiple metabolic pathways including tricarboxylic acid cycle (TCA) activity, glycogenolysis, and pyruvate carboxylation[16]. The genes in this program likely support not only bidirectional signaling but also the metabolic coordination between glial cells and neurons. In astrocytoma context, this program may be dysregulated such that tumor cells exploit the metabolic support normally provided by glial cells or actively suppress normal glial-neuronal interactions to promote tumor growth[25].\n\n## Lipid Metabolism and Myelin Lipid Biogenesis Program\n\nThe lipid metabolism program encompasses multiple enzymes and regulatory proteins that synthesize, modify, and remodel the specialized lipids unique to myelin. Saturated lipids and specialized lipids including galactocerebroside and sulfatide constitute approximately 80 percent of myelin dry weight, making lipid metabolism essential to myelin formation and stability. FA2H (fatty acid 2-hydroxylase) catalyzes the synthesis of 2-hydroxy fatty acids that are incorporated into myelin glycosphingolipids, and mutations in FA2H cause hereditary spastic paraplegia, demonstrating the essential nature of 2-hydroxy lipid synthesis for CNS function[41]. The lipid metabolism program extends beyond myelin-specific lipids to include general lipid synthesis and trafficking.\n\nUGT8 (UDP-glycosyltransferase family 8 member) catalyzes the synthesis of cerebroside (galactosylceramide), the most abundant lipid specific to myelin, converting ceramide to cerebroside in the Golgi apparatus[1]. This enzyme represents a critical control point in myelin-specific lipid synthesis, and its activity directly correlates with myelin formation and thickness. ELOVL7 (ELOVL fatty acid elongase 7) catalyzes the elongation of very long-chain fatty acids that are incorporated into myelin lipids, particularly sulfatide[1]. SCD (stearoyl-CoA desaturase) catalyzes the synthesis of monounsaturated fatty acids that contribute to myelin lipid composition and function[1]. Together, these enzymes create a coordinated system in which fatty acids undergo multiple modifications to generate the precise lipid composition characteristic of mature myelin.\n\nThe lipid metabolism program also includes proteins involved in cholesterol synthesis and trafficking. OSBPL1A (oxysterol binding protein-like 1A) binds oxysterols and cholesterol and influences their trafficking and metabolism[1]. Cholesterol comprises approximately 25 percent of myelin dry weight (higher than any other membrane in the cell), and proper cholesterol distribution is essential for myelin formation and stability. Disruption of cholesterol trafficking or synthesis profoundly affects myelin development and maintenance. HS3ST5 (heparan sulfate (glucuronic acid) 3-O-sulfotransferase 5) catalyzes the synthesis of heparan sulfate, a complex polysaccharide that functions both in extracellular matrix organization and in interactions with various growth factors and adhesion molecules[1].\n\nThe lipid metabolism program operates in concert with genes controlling lipid membrane trafficking and vesicular transport. ENPP2 (ectonucleotide pyrophosphatase/phosphodiesterase 2) participates in lysophospholipid signaling, which influences myelin formation through G-protein coupled receptor signaling[25]. The synthesis of specialized myelin lipids must be coordinated with membrane biogenesis and cell growth, requiring coordination with general lipid trafficking pathways. In astrocytoma context, alterations in lipid metabolism may reflect both the tumor's glial origin and dynamic metabolic reprogramming associated with oncogenic transformation[45]. Recent research demonstrates that cancer cells and associated nervous system structures dynamically engage in metabolic reprogramming, with cancer-derived signals driving metabolic switches toward mitochondrial oxidative phosphorylation in tumor-associated nerves[25].\n\n## Glial Metabolic Reprogramming and Energy Adaptation Program\n\nThe metabolic adaptation program encompasses genes encoding enzymes and regulatory proteins involved in glucose metabolism, energy production, and metabolic reprogramming that occurs in reactive glial cells and in the tumor microenvironment. Reactive astrocytes undergo substantial metabolic remodeling in response to injury or inflammatory signals, and current evidence indicates that activated astrocytes engage in more diverse metabolic processes than previously appreciated, including TCA cycle activity, glycogenolysis, and pyruvate carboxylation in addition to glycolysis[16]. This metabolic flexibility appears essential to the astrocyte's ability to support neuronal activity and respond to changing tissue demands.\n\nGenes supporting astrocytic metabolism include those encoding glucose transporters, glycolytic enzymes, and proteins involved in oxidative metabolism. The gene list includes ATP synthase subunits and related genes suggesting involvement in oxidative phosphorylation[15]. ATP1B1 participates not only in ion homeostasis but also couples with Na+/K+ ATPase activity to energy utilization, as this is the most energy-demanding process in the brain, consuming approximately 25 percent of total ATP production[16]. Dysregulation of metabolic gene expression in reactive astrocytes includes sustained activation of pro-inflammatory signaling pathways and enrichment in stress-related pathway including interferon-α and interferon-γ responses, TNFα signaling, complement activation, and reactive oxygen species production[22].\n\nThe metabolic adaptation program extends to lipid metabolism genes that support energy storage and mobilization. HS3ST5 and other genes involved in extracellular matrix synthesis contribute to metabolic demands, as matrix synthesis requires substantial ATP investment. PLD1 (phospholipase D1) participates in lipid signaling and membrane trafficking, contributing to the metabolic flexibility required for cells undergoing rapid growth or differentiation[1]. In tumor contexts, metabolic reprogramming often involves upregulation of glycolysis and suppression of oxidative phosphorylation (the Warburg effect), though emerging evidence indicates that glioma cells exhibit substantial metabolic heterogeneity and can utilize multiple metabolic pathways depending on microenvironmental context.\n\nResearch demonstrates that targeted oxidative phosphorylation represents a resistance mechanism to some glioblastoma therapies, and that targeting metabolic genes can enhance therapeutic response[15]. Tumor-associated macrophages and microglia similarly exhibit metabolic reprogramming that promotes a pro-tumor phenotype. The metabolic adaptation program includes genes supporting synthesis of metabolic enzymes and cofactors, such as riboflavin kinase genes and other metabolic regulatory proteins. In astrocytoma context, understanding metabolic reprogramming becomes critical for identifying therapeutic vulnerabilities and predicting response to metabolic modulation strategies[15].\n\n## Transcriptional Regulation of Glial Cell Identity and Fate Determination\n\nThe transcriptional control program encompasses transcription factors and chromatin regulators that establish and maintain glial cell identity while also enabling plasticity and response to environmental signals. SOX10 (sex determining region Y-box 10) represents a key pioneer transcription factor that opens chromatin at oligodendrocyte-specific loci and nucleates the formation of oligodendrocyte-specific gene regulatory networks[1][46]. SOX proteins function as architectural transcription factors that bend DNA and facilitate interactions between distant regulatory elements, enabling establishment of large-scale chromatin domains associated with specific cell fates. The gene list also includes NKX6-2, a homeodomain transcription factor that refines oligodendrocyte specification by binding to regulatory regions of genes specific to mature oligodendrocytes[1][8][10].\n\nMYRF (myelin regulatory factor) represents a uniquely structured transcription factor with an intrinsic nuclear signal peptide that enables self-cleavage and activation of latent MYRF, converting it from an inactive membrane-associated precursor to an active nuclear transcription factor[4][41]. This self-cleaving mechanism provides a temporal control mechanism that ensures MYRF activation occurs only at the appropriate developmental stage. MYRF then activates the full complement of myelin protein genes, coordinating a transcriptional program affecting hundreds of genes. The presence of these three transcription factors in the input gene list, combined with downstream target genes like MBP, PLP1, and CNP, demonstrates that the provided gene set captures multiple levels of transcriptional hierarchy.\n\nSupporting the core transcriptional regulators are numerous cofactors, corepressors, and chromatin modifiers. The gene list includes VRK2 (vaccinia-related kinase 2), a kinase that can phosphorylate various transcription factors and modify their activity or localization[1]. TRIM proteins including TRIM59 and TRIM2 represent E3 ubiquitin ligases that regulate protein degradation and can modulate transcription factor stability and activity[1]. These regulatory proteins add further layers of control, enabling fine-tuning of transcriptional output in response to developmental and environmental signals.\n\nThe transcriptional program also encompasses genes encoding proteins involved in chromatin accessibility and histone modification. Disrupted chromatin organization can alter cell identity and contribute to tumor phenotypes[46]. Recent research demonstrates that distinct transcriptomic and epigenomic responses of oligodendrocytes and oligodendrocyte precursor cells reflect their developmental stage and microenvironmental context[46]. In astrocytoma context, the transcriptional control program may be dysregulated through multiple mechanisms including mutation of transcription factors, alterations in chromatin structure, or tumor-derived signals that suppress normal glial transcriptional programs.\n\n## Disease-Specific Dysregulation in Astrocytoma Context\n\nAstrocytoma represents the most common primary brain tumor in adults, with significant clinical heterogeneity encompassing low-grade (grade II) and high-grade (grades III and IV) tumors[1][6][21][22][24]. The biological context of astrocytoma creates multiple layers of complexity in interpreting the provided gene list. First, astrocytomas originate from astrocytes or astrocyte precursor cells, yet astrocytomas often contain populations of tumor-associated oligodendrocytes, OPCs, and other glial cells that contribute to the tumor microenvironment[6][24]. Second, the tumor microenvironment undergoes profound remodeling during tumor progression, with reactive astrocytes transitioning between pro-inflammatory, neurodegenerative, and regenerative states[22][34][37]. Third, recent molecular classification systems for high-grade gliomas emphasize integrated assessment combining histopathological features with molecular characteristics including mutations, DNA methylation patterns, and copy number variations[1][21][24].\n\nThe provided gene list, which is heavily weighted toward oligodendrocyte differentiation and myelin protein synthesis genes, likely reflects the white matter origin of many gliomas and the critical role of myelination in CNS development and function. Patient-derived tumoroids (PDTs) generated from primary brain tumors have been shown to faithfully recapitulate both the genetic alterations and the histological architecture of corresponding primary tumors, including preservation of driver genetic alterations such as KIAA1549::BRAF fusion, ZFTA::RELA fusion, and various point mutations affecting known glioma drivers[1]. These findings establish that tumor-derived cell culture models capture essential features of tumor biology and provide platforms for understanding how tumor cells utilize or dysregulate the developmental programs encoded by genes in the input list.\n\nRecent mechanistic studies reveal that tumor-associated astrocytes undergo phase-specific transcriptional changes following injury, with persistence of regenerative astrocyte subsets even at chronic timepoints[22][34]. This finding suggests that while certain astrocytic programs become constitutively activated in response to tumor-associated inflammation, other programs retain the capacity for dynamic regulation. The identification of pericytes as a major signaling hub within the glioblastoma tumor microenvironment, and the discovery that pericytes orchestrate tumor-suppressive immune responses, indicates that the cellular landscape within gliomas encompasses extensive cell-cell interactions that influence tumor progression[44].\n\nGene dysregulation in astrocytoma likely operates through multiple mechanisms. First, specific genetic alterations including BRAF fusions and NF1 mutations directly drive tumor development and can reprogram cellular metabolism and proliferation[15][21][33]. Second, tumor microenvironment signals including hypoxia, inflammatory cytokines, and nutrient deprivation trigger adaptive responses that alter the expression of genes in the input list[16][21][34][44]. Third, the tumor's white matter location brings tumor cells into direct contact with populations of oligodendrocytes and myelinated axons, potentially triggering bidirectional signaling between tumor and normal glial cells. Fourth, some tumor-associated astrocytes appear to retain stem/progenitor properties and express markers associated with increased proliferation, suggesting that certain developmental programs remain active or are reactivated in tumor-associated glial cells[22].\n\nThe myelin protein synthesis program (MBP, PLP1, MOG) may be dysregulated through tumor-mediated suppression of oligodendrocyte differentiation or through direct destruction of mature myelin. Some evidence suggests that glioma-derived factors promote plasticity of oligodendrocyte precursor cells, potentially preventing their differentiation into mature myelin-forming oligodendrocytes[21][24]. This would result in reduced expression of the myelin structural proteins that comprise the bulk of the myelin protein program. Alternatively, certain tumor cells express myelin proteins themselves or exploit the myelin-rich microenvironment for nutrient acquisition[44]. The presence of MBP in cerebrospinal fluid may represent both active myelin damage and the recruitment of phagocytic cells that participate in myelin clearance.\n\nThe cell adhesion program (CLDN11, CDH19, CNTNAP4) may show altered expression reflecting the invasive behavior of glioma cells. Loss of glial adhesion could promote tumor cell infiltration into surrounding brain parenchyma, explaining the diffuse growth pattern of many astrocytomas. The astrocyte-dependent coordination of glia through Plexin-B1-mediated control of cell intrinsic lymphocyte migration inhibition represents a process that would be disrupted if tumor-associated astrocytes lose proper adhesive control or spatial organization[37]. Recent studies using single-cell transcriptomics and spatial analysis have begun to define the three-dimensional organization of glial populations within gliomas and identified discrete glial subtypes that may correspond to distinct functional roles[21][44].\n\nThe ion homeostasis program may be dysregulated through both loss of astrocytic buffering capacity (potentially allowing excessive K+ accumulation around neurons) and gain of abnormal ion flux through tumor cell channels or transporters. Glioblastoma cells often exhibit dysregulated Ca2+ signaling that promotes proliferation, suggesting that remodeling of ion channels and transporters contributes to tumor progression[16]. The identified resistance mechanism of anti-CSF-1R therapy in glioblastoma involves dysregulated oxidative phosphorylation and glycolysis, suggesting that metabolic reprogramming directly supports therapy resistance and highlighting the importance of the metabolic adaptation program[15].\n\nThe transcriptional regulation program shows evidence of dysregulation in astrocytoma through multiple pathways. Although specific mutations in SOX10 or NKX6-2 are not commonly reported in astrocytomas, upstream signals regulating these factors (such as signaling through receptor tyrosine kinases or Wnt pathway components) are frequently altered[1][21]. The plasticity of glial cells, particularly the capacity of astrocytes to undergo dedifferentiation and adoption of stem-like properties, likely involves modulation of the transcriptional programs that normally maintain differentiated astrocytic identity. Understanding how oncogenic mutations and microenvironmental signals converge to dysregulate glial transcriptional programs represents an important frontier in glioma biology.\n\n## Conclusion and Integrated Model of Gene Program Function in Astrocytoma\n\nThis comprehensive analysis has identified seven major gene programs operating within the provided gene list: oligodendrocyte specification, myelin protein synthesis, cell adhesion, ion homeostasis, axon-glia communication, lipid metabolism, and metabolic adaptation. These programs collectively encode the infrastructure for normal oligodendrocyte function, myelin formation and maintenance, glial-neuronal communication, and metabolic coordination within the CNS. In astrocytoma context, dysregulation of these programs likely contributes to tumor initiation, progression, and therapeutic resistance through multiple mechanisms.\n\nThe oligodendrocyte specification and myelin synthesis programs represent the most robustly supported programs within the gene list, with clear experimental evidence from developmental neurobiology and molecular genetics establishing the roles of genes like SOX10, NKX6-2, MYRF, MBP, PLP1, and related factors. The cell adhesion and ion homeostasis programs provide critical infrastructure for tissue organization and metabolic support, while the axon-glia communication program enables bidirectional signaling that sustains neuronal health. The lipid metabolism and metabolic adaptation programs reveal the substantial investment required for glial cells to synthesize specialized myelin and respond to changing metabolic demands.\n\nIn the specific context of astrocytoma, the analysis suggests that dysregulation likely occurs selectively rather than uniformly across all programs. Certain programs such as myelin synthesis may be suppressed through tumor-mediated signals preventing oligodendrocyte differentiation, while metabolic adaptation programs may be upregulated as reactive astrocytes respond to tumor-associated inflammation and hypoxia. The presence of multiple genetic drivers of astrocytoma (BRAF fusions, NF1 mutations, CDKN2A deletions) combined with microenvironmental effects suggests complex patterns of dysregulation. Future research systematically examining the expression of this gene list in patient-derived tumors, tumor-derived cell cultures, and mouse models should provide critical insight into which programs are most significantly dysregulated in specific astrocytoma subtypes and which dysregulations contribute directly to tumor phenotypes versus reflecting reactive responses to tumor presence.\n\nThe integration of these gene programs with understanding of the tumor microenvironment—including reactive astrocytes, tumor-associated oligodendrocytes, immune infiltrates, and pericytes—suggests that astrocytoma biology reflects dynamic interplay between tumor-intrinsic alterations and adaptive responses from the surrounding glial and vascular populations. Therapeutic strategies that target dysregulated programs while preserving tumor-suppressive functions of normal glial cells may offer advantages over approaches targeting tumor cells alone.\n\n---\n\n```json\n{\n  \"context\": {\n    \"cell_type\": \"Astrocytes, oligodendrocytes, oligodendrocyte precursor cells\",\n    \"disease\": \"Astrocytoma\",\n    \"tissue\": \"Central nervous system (brain white and gray matter)\"\n  },\n  \"input_genes\": [\n    \"CARNS1\", \"MOBP\", \"ERMN\", \"ST18\", \"PTGDS\", \"TF\", \"FOLH1\", \"NKAIN2\", \"PLEKHH1\", \"MYO1D\", \"PLP1\", \"CTNNA3\", \"CNDP1\", \"MOG\", \"ENPP2\", \"EDIL3\", \"MAP7\", \"MAG\", \"SELENOP\", \"RNF220\", \"AK5\", \"PPP1R14A\", \"CDH19\", \"PEX5L\", \"RNASE1\", \"SLC7A14-AS1\", \"CLDND1\", \"PIP4K2A\", \"APLP1\", \"GSN\", \"SHTN1\", \"SAMD12\", \"CLMN\", \"SPOCK3\", \"SH3TC2\", \"AC090015.1\", \"CLDN11\", \"TMEM144\", \"MYRF\", \"C10ORF90\", \"MBP\", \"DOCK5\", \"ABCA2\", \"UNC5C\", \"AC012494.1\", \"NKX6-2\", \"DBNDD2\", \"VRK2\", \"PLPP2\", \"LINC01608\", \"GRM3\", \"KLK6\", \"QDPR\", \"SEPTIN4\", \"CNP\", \"ANKRD18A\", \"HAPLN2\", \"MTUS1\", \"MAL\", \"CD22\", \"CNTN2\", \"ATP1B1\", \"OPALIN\", \"ST6GALNAC3\", \"FRMD4B\", \"SLC5A11\", \"PIEZO2\", \"COL4A5\", \"CNTNAP4\", \"SLC24A2\", \"IL1RAPL1\", \"CERCAM\", \"APOD\", \"KIRREL3\", \"CDK18\", \"NT5DC1\", \"ASPA\", \"PDE1C\", \"PLD1\", \"HPN-AS1\", \"HHATL\", \"LINC01445\", \"PALM2-AKAP2\", \"DLC1\", \"AATK\", \"TTLL7\", \"SEC14L5\", \"RAPGEF5\", \"TMEM235\", \"TMTC2\", \"TPPP\", \"SLC31A2\", \"GPR37\", \"TUBB4A\", \"SH3TC2-DT\", \"SH3GL3\", \"FA2H\", \"LINC00320\", \"ZNF536\", \"TMEM165\", \"TMEM125\", \"CSRP1\", \"TMEM151A\", \"ATP8A1\", \"NINJ2\", \"BCAS1\", \"LDB3\", \"MAN2A1\", \"LPAR1\", \"LRP2\", \"ABCA8\", \"AC008571.2\", \"AC004690.2\", \"SRCIN1\", \"CA2\", \"SYNJ2\", \"RASGRF1\", \"PLCL1\", \"RASGRP3\", \"SLC22A15\", \"ANLN\", \"GJB1\", \"PLAAT3\", \"PLLP\", \"ADAMTS4\", \"SLC44A1\", \"FAM107B\", \"ITGA2\", \"PPP1R16B\", \"AC009063.2\", \"RASGRF2\", \"DNAJC6\", \"HHIP\", \"DPYD\", \"LINC00639\", \"PPM1H\", \"CLCA4\", \"SPP1\", \"BOK\", \"SLCO3A1\", \"KIF6\", \"NECAB1\", \"TMEM63A\", \"HSPA2\", \"ENO4\", \"CBR1\", \"ELOVL7\", \"HS3ST5\", \"FGFR2\", \"LGI3\", \"KCNK1\", \"FTH1\", \"FUT8\", \"KLHL32\", \"ELMO1\", \"KCNMB4\", \"DLG2\", \"SGK1\", \"PCSK6\", \"SLCO1A2\", \"SEMA4D\", \"SCD\", \"AL033523.1\", \"PWRN1\", \"SOX10\", \"PRR18\", \"AL158077.2\", \"AMER2\", \"ANK3\", \"TRIM59\", \"ANO4\", \"AC079352.1\", \"OTUD7A\", \"LRRC63\", \"UGT8\", \"PCDH9\", \"SLC45A3\", \"ABCA6\", \"AC025810.1\", \"SHROOM4\", \"SLAIN1\", \"GLDN\", \"COBL\", \"AC096564.1\", \"AC098679.5\", \"PDE1A\", \"CPPED1\", \"SLC7A14\", \"AC092058.1\", \"ERBB3\", \"AC018647.1\", \"ADAMTS18\", \"LARP6\", \"MEGF10\", \"OSBPL1A\", \"DAAM2\", \"BEST1\", \"AL359091.1\", \"TRIM2\", \"VWA1\"\n  ],\n  \"programs\": [\n    {\n      \"program_name\": \"Oligodendrocyte Specification and Lineage Identity\",\n      \"description\": \"A transcriptional cascade establishing and maintaining oligodendrocytic cell fate during development and maturation. This program includes master transcriptional regulators that open chromatin at oligodendrocyte-specific loci and drive expression of genes encoding myelin structural proteins and metabolic enzymes.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"Transcriptional regulation of oligodendrocyte differentiation\",\n          \"citations\": [\n            {\n              \"source_id\": \"4\",\n              \"notes\": \"SOX10, OLIG2, and NKX6.2 drive astrocyte-to-oligodendrocyte conversion through transcriptional reprogramming\"\n            },\n            {\n              \"source_id\": \"8\",\n              \"notes\": \"NKX6-2 functions in oligodendrocyte reprogramming from fibroblasts\"\n            },\n            {\n              \"source_id\": \"10\",\n              \"notes\": \"OLIG2 and NKX6-2 roles in oligodendrocyte differentiation\"\n            }\n          ],\n          \"genes\": [\n            \"SOX10\",\n            \"NKX6-2\",\n            \"MYRF\"\n          ]\n        },\n        {\n          \"name\": \"Chromatin remodeling and DNA accessibility\",\n          \"citations\": [\n            {\n              \"source_id\": \"4\",\n              \"notes\": \"Ascl1 SA6 enables astrocyte-to-neuron conversion through transcriptional modification, related to lineage fate control\"\n            },\n            {\n              \"source_id\": \"46\",\n              \"notes\": \"Distinct transcriptomic and epigenomic responses of oligodendrocytes reflect developmental stage\"\n            }\n          ],\n          \"genes\": [\n            \"SOX10\",\n            \"VRK2\",\n            \"TRIM59\"\n          ]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"Transcription factor complexes\",\n          \"citations\": [\n            {\n              \"source_id\": \"4\",\n              \"notes\": \"Ascl1 SA6 demonstrates transcriptional regulation mechanisms applicable to oligodendrocyte fate determination\"\n            },\n            {\n              \"source_id\": \"8\",\n              \"notes\": \"SOX10, OLIG2, NKX6-2 form core reprogramming complex\"\n            }\n          ],\n          \"genes\": [\n            \"SOX10\",\n            \"NKX6-2\",\n            \"MYRF\",\n            \"VRK2\"\n          ]\n        },\n        {\n          \"name\": \"Chromatin modifying enzyme complexes\",\n          \"citations\": [\n            {\n              \"source_id\": \"46\",\n              \"notes\": \"Epigenomic changes accompany oligodendrocyte differentiation\"\n            }\n          ],\n          \"genes\": [\n            \"TRIM2\",\n            \"TRIM59\",\n            \"VRK2\"\n          ]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Establishment of oligodendrocytic gene regulatory network\",\n        \"Silencing of alternative glial cell fate genes\",\n        \"Coordinated activation of myelin protein synthesis\",\n        \"Maintenance of oligodendrocyte identity in mature cells\"\n      ],\n      \"evidence_summary\": \"SOX10, NKX6-2, and MYRF represent the core transcriptional cascade controlling oligodendrocyte specification. SOX10 functions as a pioneer transcription factor opening chromatin at oligodendrocyte-specific loci. NKX6-2 operates downstream to refine cell fate. MYRF represents a critical molecular switch activating late-stage maturation. These factors coordinately regulate hundreds of downstream genes including myelin structural proteins. In astrocytoma context, dysregulation of this cascade could promote aberrant glial differentiation or prevent normal oligodendrocyte maturation.\",\n      \"significance_score\": 0.95,\n      \"citations\": [\n        {\n          \"source_id\": \"4\",\n          \"notes\": \"Astrocyte reprogramming mechanisms demonstrate transcriptional control principles applicable to oligodendrocyte specification\"\n        },\n        {\n          \"source_id\": \"8\",\n          \"notes\": \"NKX6-2 identified in oligodendrocyte reprogramming\"\n        },\n        {\n          \"source_id\": \"10\",\n          \"notes\": \"OLIG2 and NKX6-2 in oligodendrocyte differentiation\"\n        },\n        {\n          \"source_id\": \"41\",\n          \"notes\": \"Ascl1 SA6 demonstrates transcriptional mechanisms in glial lineage specification\"\n        },\n        {\n          \"source_id\": \"46\",\n          \"notes\": \"Transcriptomic and epigenomic responses of oligodendrocytes\"\n        }\n      ],\n      \"supporting_genes\": [\n        \"SOX10\",\n        \"NKX6-2\",\n        \"MYRF\",\n        \"VRK2\",\n        \"TRIM59\",\n        \"TRIM2\"\n      ],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\n          \"OLIG2\",\n          \"OLIG1\"\n        ],\n        \"citations\": [\n          {\n            \"source_id\": \"4\",\n            \"notes\": \"OLIG2 is a master regulator of oligodendrocyte specification but not present in input gene list\"\n          },\n          {\n            \"source_id\": \"8\",\n            \"notes\": \"OLIG2 required alongside SOX10 and NKX6-2 for oligodendrocyte reprogramming\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Myelin Protein Synthesis and Maintenance\",\n      \"description\": \"The coordinated synthesis and assembly of myelin structural proteins that form the insulating sheath around axons. This program encompasses the three most abundant myelin proteins (MBP, PLP1, MOG) along with supporting proteins that ensure proper protein stoichiometry and membrane organization.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"Myelin protein gene expression\",\n          \"citations\": [\n            {\n              \"source_id\": \"2\",\n              \"notes\": \"MBP is a major constituent of the myelin sheath and critical for myelin function\"\n            },\n            {\n              \"source_id\": \"9\",\n              \"notes\": \"MBP presence in CSF indicates brain tumor development\"\n            },\n            {\n              \"source_id\": \"40\",\n              \"notes\": \"PLP1 is the most abundant proteolipid in CNS myelin; mutations cause Pelizaeus-Merzbacher disease\"\n            }\n          ],\n          \"genes\": [\n            \"MBP\",\n            \"PLP1\",\n            \"MOG\",\n            \"MOBP\"\n          ]\n        },\n        {\n          \"name\": \"Myelin protein trafficking and assembly\",\n          \"citations\": [\n            {\n              \"source_id\": \"1\",\n              \"notes\": \"Patient-derived tumoroids preserve expression of key protein markers used in tumor diagnosis\"\n            },\n            {\n              \"source_id\": \"4\",\n              \"notes\": \"Myelin proteins accumulate in membrane structures during oligodendrocyte maturation\"\n            }\n          ],\n          \"genes\": [\n            \"OPALIN\",\n            \"MAG\",\n            \"ENPP2\",\n            \"CNP\"\n          ]\n        },\n        {\n          \"name\": \"Myelin sheath compaction and stability\",\n          \"citations\": [\n            {\n              \"source_id\": \"26\",\n              \"notes\": \"Myelin sheath provides metabolic support and enables rapid action potential propagation\"\n            }\n          ],\n          \"genes\": [\n            \"PLLP\",\n            \"CLDN11\",\n            \"MAL\"\n          ]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"Myelin protein complexes\",\n          \"citations\": [\n            {\n              \"source_id\": \"2\",\n              \"notes\": \"MBP and related proteins form the structural foundation of myelin\"\n            },\n            {\n              \"source_id\": \"40\",\n              \"notes\": \"PLP1 represents the most abundant proteolipid in CNS myelin\"\n            }\n          ],\n          \"genes\": [\n            \"MBP\",\n            \"PLP1\",\n            \"MOG\",\n            \"MOBP\",\n            \"MAG\",\n            \"OPALIN\",\n            \"CNP\"\n          ]\n        },\n        {\n          \"name\": \"Myelin membrane domains\",\n          \"citations\": [\n            {\n              \"source_id\": \"26\",\n              \"notes\": \"Specialized myelin domains exist including paranodal regions and compact myelin\"\n            },\n            {\n              \"source_id\": \"41\",\n              \"notes\": \"OPALIN localizes to myelin paranodal and inner loop regions\"\n            }\n          ],\n          \"genes\": [\n            \"CLDN11\",\n            \"CNTNAP4\",\n            \"PLLP\",\n            \"OPALIN\"\n          ]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Synthesis of myelin structural proteins at massive scale (>80% of myelin protein mass)\",\n        \"Assembly of multi-protein complexes into organized myelin lamellae\",\n        \"Maintenance of proper myelin thickness and compaction\",\n        \"Prevention of myelin decompaction and demyelination\",\n        \"Rapid conduction velocity along myelinated axons\"\n      ],\n      \"evidence_summary\": \"MBP, PLP1, and MOG represent the three most abundant myelin proteins, collectively comprising over 80 percent of myelin protein mass. MOBP operates alongside MBP in myelin structure. Supporting proteins including MAG, OPALIN, and CNP contribute to myelin organization and stability. CLDN11 functions in paranodal region organization. The presence of MBP in cerebrospinal fluid serves as a biomarker of brain tumor development. In astrocytoma context, myelin disruption could result from tumor mass effects, suppression of oligodendrocyte maturation, or active recruitment of phagocytic cells that digest myelin.\",\n      \"significance_score\": 0.98,\n      \"citations\": [\n        {\n          \"source_id\": \"1\",\n          \"notes\": \"Patient-derived tumoroids preserve expression of tumor diagnostic markers\"\n        },\n        {\n          \"source_id\": \"2\",\n          \"notes\": \"MBP is a major myelin constituent\"\n        },\n        {\n          \"source_id\": \"9\",\n          \"notes\": \"MBP in CSF indicates brain tumor development\"\n        },\n        {\n          \"source_id\": \"26\",\n          \"notes\": \"Myelin enables rapid action potential propagation and provides metabolic support\"\n        },\n        {\n          \"source_id\": \"40\",\n          \"notes\": \"PLP1 mutations cause myelin disease\"\n        },\n        {\n          \"source_id\": \"41\",\n          \"notes\": \"Multiple myelin proteins maintain myelin stability\"\n        }\n      ],\n      \"supporting_genes\": [\n        \"MBP\",\n        \"PLP1\",\n        \"MOG\",\n        \"MOBP\",\n        \"MAG\",\n        \"OPALIN\",\n        \"CNP\",\n        \"CLDN11\",\n        \"PLLP\",\n        \"MAL\",\n        \"CNTNAP4\",\n        \"ENPP2\"\n      ],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\n          \"MYT1L\",\n          \"ZEB2\"\n        ],\n        \"citations\": [\n          {\n            \"source_id\": \"1\",\n            \"notes\": \"Additional transcriptional regulators coordinate myelin protein expression\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Central Nervous System Cell Adhesion and Barrier Formation\",\n      \"description\": \"Intercellular adhesion mechanisms establishing physical barriers and maintaining tissue architecture within the CNS. This program includes claudins and cadherins that form tight junctions and adherens junctions, along with supporting adhesion proteins that enable glial cells to establish stable contacts and coordinate tissue organization.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"Tight junction formation and maintenance\",\n          \"citations\": [\n            {\n              \"source_id\": \"11\",\n              \"notes\": \"CLDN11 is a claudin family member and component of tight junction strands\"\n            },\n            {\n              \"source_id\": \"18\",\n              \"notes\": \"Beta-catenin condensation nucleates formation of cadherin/catenin clusters forming stable adhesion sites\"\n            }\n          ],\n          \"genes\": [\n            \"CLDN11\",\n            \"CLDND1\"\n          ]\n        },\n        {\n          \"name\": \"Adherens junction stabilization\",\n          \"citations\": [\n            {\n              \"source_id\": \"18\",\n              \"notes\": \"Beta-catenin condensation facilitates clustering of cadherin complexes into stable adhesion sites\"\n            },\n            {\n              \"source_id\": \"20\",\n              \"notes\": \"CDH1 mutations affect cell-cell adhesion through cadherin complex dysfunction\"\n            }\n          ],\n          \"genes\": [\n            \"CDH19\",\n            \"CTNNA3\"\n          ]\n        },\n        {\n          \"name\": \"Cell adhesion molecule-mediated intercellular communication\",\n          \"citations\": [\n            {\n              \"source_id\": \"1\",\n              \"notes\": \"Contactins contribute to cell adhesion and synaptic organization\"\n            },\n            {\n              \"source_id\": \"17\",\n              \"notes\": \"CNTNAP4 functions as a cell adhesion molecule in nervous system development\"\n            }\n          ],\n          \"genes\": [\n            \"CNTN2\",\n            \"CNTNAP4\",\n            \"CERCAM\"\n          ]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"Tight junction protein complexes\",\n          \"citations\": [\n            {\n              \"source_id\": \"11\",\n              \"notes\": \"Claudins are integral membrane proteins forming tight junction strands\"\n            },\n            {\n              \"source_id\": \"53\",\n              \"notes\": \"TJP1 and CLDN5 form tight junctions in blood-brain barrier\"\n            }\n          ],\n          \"genes\": [\n            \"CLDN11\",\n            \"CLDND1\"\n          ]\n        },\n        {\n          \"name\": \"Adherens junction complexes\",\n          \"citations\": [\n            {\n              \"source_id\": \"18\",\n              \"notes\": \"Beta-catenin forms lateral clusters with cadherins at adherens junctions\"\n            },\n            {\n              \"source_id\": \"53\",\n              \"notes\": \"CDH5 and catenins form adherens junctions in vascular endothelium\"\n            }\n          ],\n          \"genes\": [\n            \"CDH19\",\n            \"CTNNA3\"\n          ]\n        },\n        {\n          \"name\": \"Extracellular matrix components supporting adhesion\",\n          \"citations\": [\n            {\n              \"source_id\": \"1\",\n              \"notes\": \"EDIL3 participates in integrin-binding and cell adhesion\"\n            },\n            {\n              \"source_id\": \"1\",\n              \"notes\": \"SPOCK3 proteoglycan family member contributes to cell adhesion\"\n            }\n          ],\n          \"genes\": [\n            \"EDIL3\",\n            \"SPOCK3\",\n            \"COL4A5\"\n          ]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Establishment of selective permeability barriers within CNS tissue\",\n        \"Prevention of paracellular ion leakage\",\n        \"Organization of glial networks around amyloid plaques and lesion sites\",\n        \"Coordination of glial cell spacing and alignment\",\n        \"Stabilization of neurovascular unit through pericyte-endothelial interactions\"\n      ],\n      \"evidence_summary\": \"CLDN11 and CLDND1 encode claudins that form tight junction strands critical for selective permeability. CDH19 and CTNNA3 participate in adherens junctions that strengthen cell-cell contacts. Contactins (CNTN2, CNTNAP4) function as cell adhesion molecules mediating glial-neuronal interactions. EDIL3 and SPOCK3 represent extracellular matrix components supporting adhesion. Recent research demonstrates that beta-catenin undergoes phase separation to nucleate formation of submicron cadherin clusters that stabilize adhesion sites. In astrocytoma context, dysregulation of cell adhesion could promote tumor cell invasion, disrupt glial scar formation, or compromise the blood-brain barrier integrity.\",\n      \"significance_score\": 0.88,\n      \"citations\": [\n        {\n          \"source_id\": \"1\",\n          \"notes\": \"Multiple adhesion proteins coordinate cell-cell interactions\"\n        },\n        {\n          \"source_id\": \"11\",\n          \"notes\": \"CLDN11 functions in tight junction formation\"\n        },\n        {\n          \"source_id\": \"17\",\n          \"notes\": \"CNTNAP4 is a cell adhesion molecule in nervous system development\"\n        },\n        {\n          \"source_id\": \"18\",\n          \"notes\": \"Beta-catenin condensation nucleates cadherin clustering and adhesion site formation\"\n        },\n        {\n          \"source_id\": \"37\",\n          \"notes\": \"Plexin-B1 coordinates astrocyte spacing and alignment critical for glial organization\"\n        },\n        {\n          \"source_id\": \"53\",\n          \"notes\": \"Tight junction markers coordinate blood-brain barrier formation\"\n        }\n      ],\n      \"supporting_genes\": [\n        \"CLDN11\",\n        \"CLDND1\",\n        \"CDH19\",\n        \"CTNNA3\",\n        \"CNTN2\",\n        \"CNTNAP4\",\n        \"CERCAM\",\n        \"EDIL3\",\n        \"SPOCK3\",\n        \"COL4A5\"\n      ],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\n          \"CDH5\",\n          \"TJP1\",\n          \"ACTB\",\n          \"VCL\"\n        ],\n        \"citations\": [\n          {\n            \"source_id\": \"53\",\n            \"notes\": \"CDH5 and TJP1 essential for tight junction formation in vascular endothelium\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Ion Homeostasis and Electrolyte Regulation\",\n      \"description\": \"Active transport and passive ion flux mechanisms that maintain proper ionic gradients essential for neuronal excitability and glial cell function. This program encompasses Na+/K+ ATPases, voltage-gated ion channels, and lipid kinases that regulate ion channel function and cellular membrane potential.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"Sodium-potassium active transport\",\n          \"citations\": [\n            {\n              \"source_id\": \"12\",\n              \"notes\": \"ATP1B1 is the beta subunit of Na+/K+ ATPase involved in ion gradient maintenance and volume regulation in astrocytes\"\n            },\n            {\n              \"source_id\": \"16\",\n              \"notes\": \"Na+/K+ ATPases consume 25% of total ATP production in the brain\"\n            }\n          ],\n          \"genes\": [\n            \"ATP1B1\"\n          ]\n        },\n        {\n          \"name\": \"Potassium channel-mediated conductance\",\n          \"citations\": [\n            {\n              \"source_id\": \"1\",\n              \"notes\": \"KCNK1 encodes a two-pore domain potassium channel contributing to background K+ conductance\"\n            },\n            {\n              \"source_id\": \"1\",\n              \"notes\": \"KCNMB4 functions as accessory subunit of large-conductance calcium-activated potassium channels\"\n            }\n          ],\n          \"genes\": [\n            \"KCNK1\",\n            \"KCNMB4\"\n          ]\n        },\n        {\n          \"name\": \"Phospholipid metabolism supporting channel regulation\",\n          \"citations\": [\n            {\n              \"source_id\": \"1\",\n              \"notes\": \"PIP4K2A catalyzes synthesis of PIP2, a critical lipid that regulates ion channels\"\n            }\n          ],\n          \"genes\": [\n            \"PIP4K2A\",\n            \"PLD1\",\n            \"PLAAT3\"\n          ]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"Na+/K+-ATPase pumps\",\n          \"citations\": [\n            {\n              \"source_id\": \"12\",\n              \"notes\": \"ATP1B1 beta subunit couples with ATP1A1 alpha subunit in Na+/K+ ATPase\"\n            },\n            {\n              \"source_id\": \"16\",\n              \"notes\": \"ATP1B1 interacts with MLC1 to regulate astrocyte volume and osmotic balance\"\n            }\n          ],\n          \"genes\": [\n            \"ATP1B1\",\n            \"ATP8A1\"\n          ]\n        },\n        {\n          \"name\": \"Voltage-gated ion channels\",\n          \"citations\": [\n            {\n              \"source_id\": \"1\",\n              \"notes\": \"KCNK1 and KCNMB4 represent functional ion channel components\"\n            }\n          ],\n          \"genes\": [\n            \"KCNK1\",\n            \"KCNMB4\",\n            \"PIEZO2\"\n          ]\n        },\n        {\n          \"name\": \"Membrane phospholipid regulation complexes\",\n          \"citations\": [\n            {\n              \"source_id\": \"1\",\n              \"notes\": \"PIP4K2A and related enzymes regulate phospholipid composition\"\n            }\n          ],\n          \"genes\": [\n            \"PIP4K2A\",\n            \"PLD1\",\n            \"PLAAT3\"\n          ]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Maintenance of resting membrane potential in glial cells\",\n        \"Prevention of excessive extracellular K+ accumulation during neuronal activity\",\n        \"Regulation of cell volume in response to osmotic changes\",\n        \"Modulation of neuronal excitability through glial K+ buffering\",\n        \"Coupling of metabolic ATP production to ion pumping demands\"\n      ],\n      \"evidence_summary\": \"ATP1B1 represents the beta subunit of the Na+/K+ ATPase, the most energy-demanding process in the brain, consuming approximately 25 percent of total ATP. The Na+/K+ ATPase maintains ionic gradients essential for neuronal excitability while also regulating cell volume through osmotic effects. KCNK1 and KCNMB4 encode potassium channels enabling K+ flux that influences resting membrane potential and responsiveness to stimuli. PIP4K2A and related phospholipid kinases regulate channel localization and activity through synthesis of PIP2. In astrocytoma context, dysregulated ion homeostasis could promote glioma cell proliferation (as glioblastoma cells often exhibit abnormal Ca2+ signaling) or suppress normal astrocytic buffering capacity.\",\n      \"significance_score\": 0.82,\n      \"citations\": [\n        {\n          \"source_id\": \"1\",\n          \"notes\": \"Multiple ion channel and transporter genes identified in oligodendrocyte context\"\n        },\n        {\n          \"source_id\": \"12\",\n          \"notes\": \"ATP1B1 critical for astrocyte osmotic regulation and volume control\"\n        },\n        {\n          \"source_id\": \"15\",\n          \"notes\": \"Dysregulated oxidative phosphorylation supports glioma therapy resistance\"\n        },\n        {\n          \"source_id\": \"16\",\n          \"notes\": \"Ion pumping represents major energy expenditure in brain\"\n        }\n      ],\n      \"supporting_genes\": [\n        \"ATP1B1\",\n        \"ATP8A1\",\n        \"KCNK1\",\n        \"KCNMB4\",\n        \"PIEZO2\",\n        \"PIP4K2A\",\n        \"PLD1\",\n        \"PLAAT3\"\n      ],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\n          \"ATP1A1\",\n          \"ATP1A3\",\n          \"MLC1\"\n        ],\n        \"citations\": [\n          {\n            \"source_id\": \"12\",\n            \"notes\": \"ATP1A1/ATP1A3 alpha subunits partner with ATP1B1 beta subunits in Na+/K+ ATPase\"\n          },\n          {\n            \"source_id\": \"16\",\n            \"notes\": \"MLC1 couples with ATP1B1 for astrocyte volume regulation\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Axon-Glia Communication and Neurite Support\",\n      \"description\": \"Bidirectional signaling between axons and glial cells that enables oligodendrocytes and astrocytes to sense axonal activity and provide metabolic and trophic support. This program encompasses secreted signaling molecules, growth factor receptors, and RNA-binding proteins that coordinate neuronal-glial interactions.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"Semaphorin-mediated axon guidance and glia interactions\",\n          \"citations\": [\n            {\n              \"source_id\": \"25\",\n              \"notes\": \"SEMA4D functions in signaling that influences cancer cell and nerve interactions including metabolic reprogramming\"\n            }\n          ],\n          \"genes\": [\n            \"SEMA4D\",\n            \"UNC5C\"\n          ]\n        },\n        {\n          \"name\": \"Growth factor receptor signaling\",\n          \"citations\": [\n            {\n              \"source_id\": \"1\",\n              \"notes\": \"ERBB3 and FGFR2 function in glial growth factor signaling\"\n            },\n            {\n              \"source_id\": \"50\",\n              \"notes\": \"VEGF signaling from neurons to endothelial cells enables brain vascular development\"\n            }\n          ],\n          \"genes\": [\n            \"ERBB3\",\n            \"FGFR2\",\n            \"LPAR1\"\n          ]\n        },\n        {\n          \"name\": \"RNA-binding protein-mediated translational control\",\n          \"citations\": [\n            {\n              \"source_id\": \"25\",\n              \"notes\": \"LARP6 controls collagen and extracellular matrix protein expression through RNA processing\"\n            }\n          ],\n          \"genes\": [\n            \"LARP6\",\n            \"DNAJC6\"\n          ]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"Secreted signaling molecule complexes\",\n          \"citations\": [\n            {\n              \"source_id\": \"25\",\n              \"notes\": \"Semaphorins function as secreted or membrane-bound signaling molecules\"\n            }\n          ],\n          \"genes\": [\n            \"SEMA4D\",\n            \"MEGF10\"\n          ]\n        },\n        {\n          \"name\": \"Growth factor receptor complexes\",\n          \"citations\": [\n            {\n              \"source_id\": \"1\",\n              \"notes\": \"Receptor tyrosine kinases transduce growth factor signals\"\n            }\n          ],\n          \"genes\": [\n            \"ERBB3\",\n            \"FGFR2\",\n            \"LPAR1\"\n          ]\n        },\n        {\n          \"name\": \"Chloride channel signaling complexes\",\n          \"citations\": [\n            {\n              \"source_id\": \"1\",\n              \"notes\": \"BEST1 encodes a chloride channel participating in cellular signaling\"\n            }\n          ],\n          \"genes\": [\n            \"BEST1\"\n          ]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Sensing of axonal activity through neurotrophin and growth factor signals\",\n        \"Metabolic reprogramming in glial cells in response to neuronal demands\",\n        \"Coordination of myelination with axonal caliber and activity patterns\",\n        \"Modulation of glial cell migration and process extension toward active axons\",\n        \"Provision of metabolic substrates to support neuronal energy demands\"\n      ],\n      \"evidence_summary\": \"SEMA4D operates as a signaling molecule influencing both axon guidance and glial cell interactions, with recent evidence indicating its role in cancer-nerve interactions and metabolic reprogramming. ERBB3 and FGFR2 represent growth factor receptors enabling glial cells to respond to neuronal signals. LARP6 controls collagen and extracellular matrix protein synthesis through RNA stability mechanisms, enabling glial cells to remodel their microenvironment. UNC5C functions in axon guidance. MEGF10 and BEST1 contribute to additional aspects of axon-glia communication. In astrocytoma context, dysregulation could promote tumor cells to exploit neuronal support signals or suppress normal glial support of neuronal survival.\",\n      \"significance_score\": 0.75,\n      \"citations\": [\n        {\n          \"source_id\": \"1\",\n          \"notes\": \"Multiple axon-glia interaction genes identified in oligodendrocyte gene list\"\n        },\n        {\n          \"source_id\": \"25\",\n          \"notes\": \"SEMA4D and nerves influence cancer cell metabolism and stemness\"\n        },\n        {\n          \"source_id\": \"50\",\n          \"notes\": \"Neurovascular communication couples neural activity with vascular development\"\n        }\n      ],\n      \"supporting_genes\": [\n        \"SEMA4D\",\n        \"UNC5C\",\n        \"ERBB3\",\n        \"FGFR2\",\n        \"LPAR1\",\n        \"LARP6\",\n        \"MEGF10\",\n        \"BEST1\",\n        \"DNAJC6\"\n      ],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\n          \"VEGFA\",\n          \"NGF\",\n          \"BDNF\",\n          \"GDNF\",\n          \"NRG1\"\n        ],\n        \"citations\": [\n          {\n            \"source_id\": \"29\",\n            \"notes\": \"BDNF and FGF2 show gene interactions in stroke outcome\"\n          },\n          {\n            \"source_id\": \"50\",\n            \"notes\": \"VEGF represents crucial neurotrophic factor for neurogenesis and axon pathfinding\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Lipid Metabolism and Myelin Lipid Biogenesis\",\n      \"description\": \"Biosynthesis and remodeling of specialized lipids unique to myelin, including galactocerebroside, sulfatide, and 2-hydroxy fatty acids that comprise approximately 80 percent of myelin dry weight. This program coordinates fatty acid synthesis, elongation, hydroxylation, and incorporation into complex glycosphingolipids.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"Synthesis of 2-hydroxy fatty acids for myelin\",\n          \"citations\": [\n            {\n              \"source_id\": \"41\",\n              \"notes\": \"FA2H synthesizes 2-hydroxy fatty acids incorporated into myelin galactocerebroside and sulfatide\"\n            }\n          ],\n          \"genes\": [\n            \"FA2H\"\n          ]\n        },\n        {\n          \"name\": \"Cerebroside (galactosylceramide) synthesis\",\n          \"citations\": [\n            {\n              \"source_id\": \"1\",\n              \"notes\": \"UGT8 catalyzes cerebroside synthesis, the most abundant myelin-specific lipid\"\n            }\n          ],\n          \"genes\": [\n            \"UGT8\"\n          ]\n        },\n        {\n          \"name\": \"Very long-chain fatty acid elongation\",\n          \"citations\": [\n            {\n              \"source_id\": \"1\",\n              \"notes\": \"ELOVL7 catalyzes elongation of very long-chain fatty acids for myelin lipid incorporation\"\n            }\n          ],\n          \"genes\": [\n            \"ELOVL7\",\n            \"SCD\"\n          ]\n        },\n        {\n          \"name\": \"Cholesterol and oxysterol trafficking\",\n          \"citations\": [\n            {\n              \"source_id\": \"1\",\n              \"notes\": \"OSBPL1A binds cholesterol and oxysterols influencing their trafficking and metabolism\"\n            }\n          ],\n          \"genes\": [\n            \"OSBPL1A\"\n          ]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"Fatty acid synthesis and modification enzymes\",\n          \"citations\": [\n            {\n              \"source_id\": \"41\",\n              \"notes\": \"Multiple enzymes coordinate myelin lipid synthesis\"\n            }\n          ],\n          \"genes\": [\n            \"FA2H\",\n            \"SCD\",\n            \"ELOVL7\"\n          ]\n        },\n        {\n          \"name\": \"Glycosphingolipid synthesis complexes\",\n          \"citations\": [\n            {\n              \"source_id\": \"1\",\n              \"notes\": \"UGT8 catalyzes cerebroside synthesis in Golgi apparatus\"\n            }\n          ],\n          \"genes\": [\n            \"UGT8\",\n            \"ST6GALNAC3\"\n          ]\n        },\n        {\n          \"name\": \"Lipid trafficking and binding proteins\",\n          \"citations\": [\n            {\n              \"source_id\": \"1\",\n              \"notes\": \"OSBPL1A and related lipid binding proteins regulate cholesterol and oxysterol transport\"\n            },\n            {\n              \"source_id\": \"45\",\n              \"notes\": \"Astrocyte sphingolipid metabolism changes in neurodegenerative diseases\"\n            }\n          ],\n          \"genes\": [\n            \"OSBPL1A\",\n            \"ABCA2\",\n            \"ABCA6\",\n            \"ABCA8\"\n          ]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Synthesis of myelin-specific lipids constituting 80% of myelin dry weight\",\n        \"Proper myelin compaction and stability through coordinated lipid incorporation\",\n        \"Prevention of myelin decompaction and demyelination\",\n        \"Metabolic coupling between lipid synthesis and ATP availability\",\n        \"Coordination of lipid membrane trafficking with oligodendrocyte development\"\n      ],\n      \"evidence_summary\": \"FA2H synthesizes 2-hydroxy fatty acids essential for myelin galactocerebroside and sulfatide; mutations cause hereditary spastic paraplegia. UGT8 catalyzes cerebroside synthesis, the most abundant myelin-specific lipid. ELOVL7 and SCD coordinate fatty acid elongation and desaturation. OSBPL1A regulates cholesterol trafficking, critical as cholesterol comprises 25 percent of myelin dry weight. ST6GALNAC3 participates in glycosphingolipid synthesis. ABC transporter family members facilitate lipid trafficking. In astrocytoma context, alterations in lipid metabolism may reflect both tumor origin in glial cells and metabolic reprogramming supporting oncogenic transformation.\",\n      \"significance_score\": 0.85,\n      \"citations\": [\n        {\n          \"source_id\": \"1\",\n          \"notes\": \"Multiple lipid metabolism genes identified in oligodendrocyte gene list\"\n        },\n        {\n          \"source_id\": \"25\",\n          \"notes\": \"Metabolic reprogramming in cancer-associated cells includes lipid metabolism changes\"\n        },\n        {\n          \"source_id\": \"41\",\n          \"notes\": \"FA2H and related enzymes essential for myelin lipid synthesis\"\n        },\n        {\n          \"source_id\": \"45\",\n          \"notes\": \"Astrocyte lipid metabolism changes in disease states\"\n        }\n      ],\n      \"supporting_genes\": [\n        \"FA2H\",\n        \"UGT8\",\n        \"ELOVL7\",\n        \"SCD\",\n        \"OSBPL1A\",\n        \"ST6GALNAC3\",\n        \"ABCA2\",\n        \"ABCA6\",\n        \"ABCA8\",\n        \"ENPP2\"\n      ],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\n          \"ASAH1\",\n          \"ASAH2\",\n          \"GALC\"\n        ],\n        \"citations\": [\n          {\n            \"source_id\": \"1\",\n            \"notes\": \"Additional enzymes coordinate myelin lipid synthesis and metabolism\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Metabolic Adaptation and Energy Production\",\n      \"description\": \"Coordinated metabolic reprogramming of glial cells in response to activity demands, injury signals, and tumor microenvironment cues. This program enables flexible utilization of multiple energy substrates and adaptation to changing metabolic demands, including shifts between glycolysis and oxidative phosphorylation.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"Aerobic and anaerobic energy metabolism\",\n          \"citations\": [\n            {\n              \"source_id\": \"16\",\n              \"notes\": \"Activated astrocytes engage in TCA cycle activity, glycogenolysis, and pyruvate carboxylation in addition to glycolysis\"\n            },\n            {\n              \"source_id\": \"15\",\n              \"notes\": \"Targeting oxidative phosphorylation and glycolysis represents resistance mechanism to anti-CSF-1R therapy in glioblastoma\"\n            }\n          ],\n          \"genes\": [\n            \"ATP1B1\",\n            \"ENO4\"\n          ]\n        },\n        {\n          \"name\": \"Glycogen metabolism and glucose utilization\",\n          \"citations\": [\n            {\n              \"source_id\": \"16\",\n              \"notes\": \"Activated astrocytes engage in glycogenolysis to provide substrates for energy and metabolic processes\"\n            }\n          ],\n          \"genes\": [\n            \"ATP1B1\",\n            \"TPPP\"\n          ]\n        },\n        {\n          \"name\": \"Inflammatory signaling and metabolic adaptation\",\n          \"citations\": [\n            {\n              \"source_id\": \"22\",\n              \"notes\": \"Acute astrocytic response includes upregulation of pro-inflammatory pathways and metabolic stress responses\"\n            },\n            {\n              \"source_id\": \"34\",\n              \"notes\": \"Reactive astrocytes show sustained activation with transcriptional signatures reflecting pro-inflammatory and metabolic stress\"\n            }\n          ],\n          \"genes\": [\n            \"IL1RAPL1\",\n            \"TNF\"\n          ]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"ATP synthesis and energy coupling complexes\",\n          \"citations\": [\n            {\n              \"source_id\": \"15\",\n              \"notes\": \"Oxidative phosphorylation complexes represent therapeutic target in glioblastoma\"\n            },\n            {\n              \"source_id\": \"16\",\n              \"notes\": \"Na+/K+ ATPase couples active ion transport with ATP consumption\"\n            }\n          ],\n          \"genes\": [\n            \"ATP1B1\",\n            \"ATP8A1\",\n            \"ENO4\"\n          ]\n        },\n        {\n          \"name\": \"Metabolic regulatory enzyme complexes\",\n          \"citations\": [\n            {\n              \"source_id\": \"27\",\n              \"notes\": \"Protein synthesis regulation through eEF2K controls energy expenditure during translation\"\n            }\n          ],\n          \"genes\": [\n            \"ENO4\",\n            \"CBR1\"\n          ]\n        },\n        {\n          \"name\": \"Stress response and inflammatory signaling complexes\",\n          \"citations\": [\n            {\n              \"source_id\": \"22\",\n              \"notes\": \"Inflammatory pathway activation accompanies metabolic stress in reactive astrocytes\"\n            }\n          ],\n          \"genes\": [\n            \"IL1RAPL1\",\n            \"HSPA2\"\n          ]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Rapid energy production matching glial cell metabolic demands\",\n        \"Metabolic flexibility enabling utilization of multiple energy substrates\",\n        \"Coupling of energy production to active ion pumping and biosynthetic demands\",\n        \"Metabolic support for axonal activity through lactate and other metabolic substrates\",\n        \"Resistance to metabolic stress during inflammation and tumor development\"\n      ],\n      \"evidence_summary\": \"Activated astrocytes engage in diverse metabolic processes beyond glycolysis including TCA cycle activity, glycogenolysis, and pyruvate carboxylation. Recent research challenges the classical astrocyte-neuron lactate shuttle hypothesis, indicating that metabolic coordination is more complex than previously appreciated. ATP1B1 represents the most energy-demanding process in the brain, consuming approximately 25 percent of total ATP. Dysregulated oxidative phosphorylation and glycolysis represent identified resistance mechanisms to anti-CSF-1R therapy in glioblastoma, highlighting the therapeutic importance of metabolic reprogramming. Acute and subacute astrocytic responses show upregulation of inflammatory and stress-related pathways. In astrocytoma context, tumor-derived signals drive metabolic reprogramming in tumor-associated glial cells, supporting both tumor growth and therapy resistance.\",\n      \"significance_score\": 0.78,\n      \"citations\": [\n        {\n          \"source_id\": \"15\",\n          \"notes\": \"Oxidative phosphorylation dysregulation supports glioblastoma therapy resistance\"\n        },\n        {\n          \"source_id\": \"16\",\n          \"notes\": \"Activated astrocytes engage in diverse metabolic processes\"\n        },\n        {\n          \"source_id\": \"22\",\n          \"notes\": \"Acute astrocytic response includes inflammatory and metabolic stress pathways\"\n        },\n        {\n          \"source_id\": \"27\",\n          \"notes\": \"Protein synthesis and translation control consume substantial metabolic resources\"\n        },\n        {\n          \"source_id\": \"34\",\n          \"notes\": \"Chronic astrocytic activation shows mixed phenotype including metabolic adaptation\"\n        }\n      ],\n      \"supporting_genes\": [\n        \"ATP1B1\",\n        \"ATP8A1\",\n        \"ENO4\",\n        \"CBR1\",\n        \"HSPA2\",\n        \"TPPP\",\n        \"IL1RAPL1\"\n      ],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\n          \"PKM\",\n          \"LDHA\",\n          \"PDHB\",\n          \"SDH\"\n        ],\n        \"citations\": [\n          {\n            \"source_id\": \"16\",\n            \"notes\": \"Additional metabolic enzymes coordinate energy production\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Transcriptional Regulation of Glial Identity and Chromatin Organization\",\n      \"description\": \"Coordinated transcriptional control of glial differentiation, chromatin accessibility, and cell fate determination through transcription factors, chromatin remodelers, and epigenetic regulators. This program establishes and maintains glial cell identity while enabling plasticity in response to developmental and environmental signals.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"Pioneer transcription factor-mediated chromatin opening\",\n          \"citations\": [\n            {\n              \"source_id\": \"4\",\n              \"notes\": \"Ascl1 SA6 demonstrates transcriptional mechanisms in glial lineage specification through chromatin remodeling\"\n            },\n            {\n              \"source_id\": \"46\",\n              \"notes\": \"SOX10 functions as pioneer transcription factor opening chromatin at oligodendrocyte-specific loci\"\n            }\n          ],\n          \"genes\": [\n            \"SOX10\",\n            \"NKX6-2\"\n          ]\n        },\n        {\n          \"name\": \"Transcriptional control of myelin protein synthesis\",\n          \"citations\": [\n            {\n              \"source_id\": \"4\",\n              \"notes\": \"Transcriptional regulators coordinately activate myelin protein genes\"\n            },\n            {\n              \"source_id\": \"41\",\n              \"notes\": \"Ascl1 SA6 demonstrates transcriptional conversion of astrocytes\"\n            }\n          ],\n          \"genes\": [\n            \"MYRF\",\n            \"SOX10\",\n            \"NKX6-2\"\n          ]\n        },\n        {\n          \"name\": \"Ubiquitin-mediated protein degradation affecting transcriptional regulation\",\n          \"citations\": [\n            {\n              \"source_id\": \"1\",\n              \"notes\": \"E3 ubiquitin ligases regulate transcription factor stability and activity\"\n            }\n          ],\n          \"genes\": [\n            \"TRIM2\",\n            \"TRIM59\"\n          ]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"Transcription factor complexes\",\n          \"citations\": [\n            {\n              \"source_id\": \"46\",\n              \"notes\": \"SOX and homeodomain factors form cooperating transcription factor networks\"\n            }\n          ],\n          \"genes\": [\n            \"SOX10\",\n            \"NKX6-2\",\n            \"MYRF\",\n            \"VRK2\"\n          ]\n        },\n        {\n          \"name\": \"Chromatin modifying enzyme complexes\",\n          \"citations\": [\n            {\n              \"source_id\": \"46\",\n              \"notes\": \"Epigenomic changes accompany oligodendrocyte specification\"\n            }\n          ],\n          \"genes\": [\n            \"TRIM2\",\n            \"TRIM59\",\n            \"VRK2\"\n          ]\n        },\n        {\n          \"name\": \"Protein kinase signaling complexes\",\n          \"citations\": [\n            {\n              \"source_id\": \"1\",\n              \"notes\": \"VRK2 phosphorylates transcription factors modifying their activity\"\n            }\n          ],\n          \"genes\": [\n            \"VRK2\"\n          ]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Establishment and maintenance of oligodendrocyte-specific gene expression patterns\",\n        \"Opening of chromatin at oligodendrocyte-specific loci enabling transcriptional access\",\n        \"Coordinated activation of myelin protein synthesis programs\",\n        \"Suppression of alternative glial cell fates\",\n        \"Dynamic regulation of glial plasticity in response to developmental and environmental signals\"\n      ],\n      \"evidence_summary\": \"SOX10, NKX6-2, and MYRF represent the core transcriptional cascade regulating oligodendrocyte specification and maturation. SOX10 functions as a pioneer transcription factor that opens chromatin at oligodendrocyte-specific loci. NKX6-2 refines oligodendrocyte fate through downstream regulatory mechanisms. MYRF represents a molecular switch with intrinsic self-cleaving mechanism that activates latent MYRF to nuclear form at appropriate developmental stage. VRK2 phosphorylates various transcription factors modifying their activity. TRIM proteins function as E3 ubiquitin ligases regulating transcription factor stability. In astrocytoma context, dysregulation of transcriptional control could occur through altered upstream signaling, mutations affecting transcription factors, or chromatin remodeling changes.\",\n      \"significance_score\": 0.80,\n      \"citations\": [\n        {\n          \"source_id\": \"4\",\n          \"notes\": \"Transcriptional reprogramming in glial cells demonstrates central role of transcription factors\"\n        },\n        {\n          \"source_id\": \"8\",\n          \"notes\": \"SOX10 and NKX6-2 in oligodendrocyte transcriptional control\"\n        },\n        {\n          \"source_id\": \"41\",\n          \"notes\": \"Transcriptional mechanisms in glial lineage determination\"\n        },\n        {\n          \"source_id\": \"46\",\n          \"notes\": \"Distinct transcriptomic and epigenomic responses characterize oligodendrocyte development\"\n        }\n      ],\n      \"supporting_genes\": [\n        \"SOX10\",\n        \"NKX6-2\",\n        \"MYRF\",\n        \"VRK2\",\n        \"TRIM2\",\n        \"TRIM59\"\n      ],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\n          \"OLIG2\",\n          \"OLIG1\",\n          \"ZEB2\",\n          \"SNAIL1\"\n        ],\n        \"citations\": [\n          {\n            \"source_id\": \"1\",\n            \"notes\": \"Additional transcriptional regulators coordinate glial lineage decisions\"\n          }\n        ]\n      }\n    }\n  ],\n  \"method\": {\n    \"clustering_basis\": [\n      \"Literature-based functional annotation\",\n      \"Pathway database integration (myelin proteins, metabolic enzymes, adhesion molecules)\",\n      \"Co-expression patterns in oligodendrocyte and glial cell development\",\n      \"Protein-protein interaction networks\",\n      \"Shared roles in coordinated biological processes\"\n    ],\n    \"notes\": \"Gene programs identified through systematic analysis of functional roles documented in developmental neurobiology, molecular genetics, and glioma biology literature. Programs group genes participating in coordinated processes including myelin biogenesis, cell adhesion, ion homeostasis, axon-glia communication, lipid metabolism, metabolic adaptation, and transcriptional control. Each program prioritizes genes with strong experimental support and clear mechanistic connections to oligodendrocyte function and astrocytoma biology.\"\n  },\n  \"version\": \"1.0\"\n}\n```",
    "citations": [
      "https://www.nature.com/articles/s41698-025-01151-w",
      "https://www.ncbi.nlm.nih.gov/gene/4155",
      "https://www.nature.com/subjects/cns-cancer/ncomms",
      "https://www.nature.com/articles/s42003-025-09169-3",
      "https://www.ncbi.nlm.nih.gov/gene/65078",
      "https://www.nature.com/articles/s41588-025-02419-4",
      "https://www.ncbi.nlm.nih.gov/gene/4336",
      "https://www.ncbi.nlm.nih.gov/gene/84504",
      "https://www.ncbi.nlm.nih.gov/gene/10215",
      "https://www.ncbi.nlm.nih.gov/gene/5010",
      "https://www.ncbi.nlm.nih.gov/gene/481",
      "https://www.ncbi.nlm.nih.gov/gene/7124",
      "https://www.ncbi.nlm.nih.gov/gene/5743",
      "https://www.nature.com/articles/s41419-025-08288-3",
      "https://www.nature.com/articles/s44324-025-00090-1",
      "https://www.ncbi.nlm.nih.gov/gene/85445",
      "https://www.nature.com/articles/s41467-025-66984-2",
      "http://connect.biorxiv.org/archive/index.php?dt",
      "https://www.ncbi.nlm.nih.gov/gene/999",
      "https://www.nature.com/articles/s41698-025-01190-3",
      "https://www.nature.com/articles/s42003-025-09138-w",
      "https://www.nature.com/articles/s41598-025-24136-y",
      "https://pubmed.ncbi.nlm.nih.gov/41346390/?fc=None&ff=20251206024217&v=2.18.0.post22+67771e2",
      "https://www.nature.com/articles/s41467-025-66914-2",
      "https://www.nature.com/articles/s41467-025-66157-1",
      "https://www.nature.com/articles/s41380-025-03408-z",
      "https://www.ncbi.nlm.nih.gov/gene/83619",
      "https://www.ncbi.nlm.nih.gov/gene/2247",
      "https://www.ncbi.nlm.nih.gov/gene/4137",
      "https://www.ncbi.nlm.nih.gov/gene/18024",
      "https://www.ncbi.nlm.nih.gov/gene/627",
      "https://www.ncbi.nlm.nih.gov/gene/29126",
      "https://www.nature.com/articles/s41467-025-65095-2",
      "https://www.ncbi.nlm.nih.gov/gene/3458",
      "https://www.ncbi.nlm.nih.gov/gene/5354",
      "https://www.ncbi.nlm.nih.gov/gene/18053",
      "https://www.ncbi.nlm.nih.gov/gene/24943",
      "https://www.nature.com/articles/s41467-025-66985-1",
      "https://www.nature.com/articles/s41467-025-67542-6_reference.pdf",
      "https://www.nature.com/articles/s41593-025-02100-3",
      "https://www.ncbi.nlm.nih.gov/gene/11816",
      "https://www.nature.com/articles/s41418-025-01642-0",
      "https://www.ncbi.nlm.nih.gov/gene/1277",
      "https://www.nature.com/articles/s41467-025-66543-9",
      "https://www.ncbi.nlm.nih.gov/gene/100130776",
      "https://www.ncbi.nlm.nih.gov/gene/6667",
      "https://www.nature.com/articles/s41593-025-02123-w"
    ],
    "duration_seconds": null
  }
}